Imdelltra plus Imfinzi cuts death risk 58% in extensive‑stage small‑cell lung cancer trial
Amgen and AstraZeneca reported that the combination of Imdelltra (tarlatamab) with Imfinzi (durvalumab) reduced the hazard of death by 58% versus Imfinzi alone in the Phase III DeLLphi‑305 trial for first‑line maintenance treatment of extensive‑stage small‑cell lung cancer. The interim analysis showed median overall survival of 21.1 months with the combo compared with 12.7 months for Imfinzi alone. The study enrolled 563 patients who had not progressed after induction therapy.
Why it matters
Amgen expects the new indication to drive annual sales exceeding $2.5 billion by 2030, according to its own estimate. The company also reported $288 million of Imdelltra sales in Q2 2026, up 115% year‑over‑year, suggesting a strong commercial upside.
Key facts
- 1The hazard ratio for death was 0.42, a 58% relative risk reduction. astrazeneca.com
- 2Median overall survival was 21.1 months with the combination versus 12.7 months with Imfinzi alone. astrazeneca.com
- 3The trial randomized 563 patients who completed induction therapy. astrazeneca.com
- 4Grade 3 or higher treatment‑related adverse events occurred in 20.9% of patients on the combination versus 10.8% on Imfinzi alone. astrazeneca.com
Open questions
- Imdelltra US list price is reported as $30,000 per cycle and as $300,000 per cycle.
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.